Revance Therapeutics
RVNC

From June 30, 2024 to September 30, 2024 Issuance of common stock related to stock awards, net of cancellation Issuance of common stock upon exercise of stock options Shares withheld related to net settlement of stock awards

From December 31, 2023 to March 31, 2024 Issuance of common stock in connection with follow-on offering Issuance of common stock related to stock awards, net of cancellation Issuance of common stock upon exercise of stock options Shares withheld related to net settlement of stock awards

Common stock offered 16,000,000 shares by the company

From December 31, 2022 to December 31, 2023 Issuance of common stock related to ATM, net of commissions and issuance costs Issuance of common stock related to stock awards, net of cancellation Issuance of common stock upon exercise of stock options Issuance of common stock related to 2014 ESPP Shares withheld related to net settlement of stock awards

From June 30, 2023 to September 30, 2023 Issuance of common stock related to stock awards Issuance of common stock upon exercise of stock options Shares withheld related to net settlement of stock awards Cancellation of stock awards, net of issuance

From December 31, 2022 to March 31, 2023 Issuance of common stock related to RSUs and PSUs Issuance of common stock upon exercise of stock options Shares withheld related to net settlement of RSAs Cancellation of RSAs, net of issuance

From December 31, 2021 to December 31, 2022 Issuance of common stock upon exercise of stock options Issuance of RSAs and PSAs, net of cancellations Issuance of common stock in connection with at-the-market offering, net of issuance costs Issuance of common stock relating to employee stock purchase plan Shares withheld related to net settlement of RSAs

From June 30, 2022 to September 30, 2022 Issuance of common stock in connection with follow-on offering Issuance of common stock upon exercise of stock options Issuance of restricted stock awards and performance stock awards, net of cancellation Shares withheld related to net settlement of restricted stock awards

From March 31, 2022 to June 30, 2022 Issuance of common stock in connection with at-the-market offerings Issuance of common stock relating to employee stock purchase plan Issuance of common stock upon exercise of stock options Issuance of restricted stock awards and performance stock awards, net of cancellation Shares withheld related to net settlement of restricted stock awards

From December 31, 2021 to March 31, 2022 Issuance of common stock in connection with at-the-market offerings Issuance of common stock upon exercise of stock options Issuance of restricted stock awards and performance stock awards, net of cancellation Shares withheld related to net settlement of restricted stock awards

From December 31, 2020 to December 31, 2021 Issuance of common stock upon exercise of stock options Issuance of restricted stock awards and performance stock awards, net of cancellations Issuance of common stock in connection with at-the-market offering, net of issuance costs Issuance of common stock relating to employee stock purchase plan Shares withheld related to net settlement of restricted stock awards

From June 30, 2021 to September 30, 2021 Issuance of restricted stock awards and performance stock awards, net of cancellation Issuance of common stock upon exercise of stock options and warrants Shares withheld related to net settlement of restricted stock awards

From March 31,2021 to June 30,2021 Issuance of restricted stock awards and performance stock awards, net of cancellation Issuance of common stock upon exercise of stock options and warrants Issuance of common stock relating to employee stock purchase plan Shares withheld related to net settlement of restricted stock awards

From December 31, 2020 To March 31, 2021 Issuance of restricted stock awards and performance stock awards, net of cancellation Issuance of common stock in connection with at-the-market offerings Issuance of common stock upon exercise of stock options and warrants Shares withheld related to net settlement of restricted stock awards

From December 31, 2019 to December 31, 2020 Issuance of common stock in connection with the HintMD Acquisition Issuance of restricted stock awards and performance stock awards, net of cancellation Issuance of common stock in connection with at-the-market offering, net of issuance costs of $211 Issuance of common stock in connection with the Teoxane Agreement Issuance of common stock in connection with offerings, net of issuance costs of $44 Issuance of common stock upon exercise of stock options and warrants Issuance of common stock relating to employee stock purchase plan Net settlement of restricted stock awards for employee taxes

From June 30, 2020 to September 30, 2020 Issuance of common stock in connection with the HintMD Acquisition Issuance of restricted stock awards and performance stock awards, net of cancellation Issuance of common stock upon exercise of stock options and warrants Net settlement of restricted stock awards for employee taxes

From March 31, 2020 to June 30,2020 Issuance of restricted stock awards and performance stock awards, net of cancellation Issuance of common stock upon exercise of stock options and warrants Issuance of common stock relating to employee stock purchase plan Net settlement of restricted stock awards for employee taxes

From December 31, 2019 to March 31, 2020 Issuance of common stock in connection with the Teoxane Agreement Issuance of restricted stock awards and performance stock awards, net of cancellation Issuance of common stock upon exercise of stock options and warrants Net settlement of restricted stock awards for employee taxes

From December 31, 2018 to December 31, 2019 Issuance of common stock relating to employee stock purchase plan Issuance of common stock in connection with at-the-market offering, net of issuance costs of $265 Issuance of common stock in connection with the 2019 offerings, net of issuance costs of $770 Issuance of common stock upon exercise of stock options Issuance of restricted stock awards, net of cancellation Net settlement of restricted stock awards for employee taxes

from June 30, 2019 to September 30, 2019 Issuance of restricted stock awards, net of cancellation Net settlement of restricted stock awards for employee taxes

from March 31, 2019 to June 30, 2019 Issuance of common stock upon exercise of stock options Issuance of restricted stock awards, net of cancellation Net settlement of restricted stock awards for employee taxes Issuance of common stock relating to employee stock purchase plan

from December 31, 2018 to March 31, 2019 Issuance of common stock in connection with the 2019 follow-on offering Issuance of common stock upon exercise of stock options Issuance of restricted stock awards, net of cancellation Net settlement of restricted stock awards for employee taxes

from December 31, 2017 to December 31, 2018 Issuance of common stock relating to employee stock purchase plan Issuance of common stock upon exercise of stock options Issuance of restricted stock awards, net of cancellation Net settlement of restricted stock awards for employee taxes

from December 31, 2016 to December 31, 2017 Issuance of common stock relating to employee stock purchase plan Issuance of common stock in connection with At-The-Market offering, net of issuance costs of $603 Issuance of common stock in connection with the 2017 follow-on offering, net of issuance costs of $535 Issuance of common stock upon net exercise of warrants Issuance of common stock upon exercise of stock options Issuance of restricted stock awards, net of repurchase Net settlement of restricted stock awards to settle employee taxes

from December 31, 2015 to December 31, 2016 Issuance of common stock relating to employee stock purchase plan Issuance of common stock upon exercise of stock options Issuance of restricted stock awards, net of repurchase Vested restricted stock awards used to pay for taxes

from December 31, 2014 to December 31, 2015 Issuance of common stock relating to employee stock purchase plan Issuance of common stock in connection with At-The-Market offering, net of issuance costs Issuance of common stock in connection with the 2015 follow-on offering, net of issuance costs Issuance of common stock upon net exercise of warrants Issuance of common stock upon exercise of stock options Issuance of restricted stock awards, net of repurchase Vested restricted stock awards used to pay for taxes

On November 9, 2015, we completed a follow-on public offering, pursuant to which we issued 3,737,500 shares of common stock at $36.00 per share, including the exercise of the underwriters’ option to purchase 487,500 additional shares of common stock, for gross proceeds of $134.6 million.

from December 31,2013 to December 31,2014 Issuance of common stock relating to employee stock purchase plan Conversion of preferred stock to common stock in connection with initial public offering Issuance of common stock in connection with initial public offering, net of underwriting discounts, commissions and issuance costs of $11,800 Issuance of common stock upon conversion of 2013 convertible notes in connection with initial public offering Issuance of common stock upon net exercise of common stock warrants and related extinguishment of warrant liability in connection with initial public offering Issuance of common stock in connection with follow on offering, net of underwriting discounts, commissions and issuance costs of $9,000 Issuance of common stock upon net exercise of warrant Issuance of common stock upon exercise of stock options Issuance of restricted stock awards, net of repurchase Issuance of common stock at $15.45 per share for services rendered The conversion of all outstanding shares of our convertible preferred stock into an aggregate of 8,689,999 shares of our common stock, which will occur upon the closing of this offering;the automatic conversion of the $23.65 million in aggregate principal amount of convertible promissory notes issued in the fourth quarter of 2013 and January 2014, or the 2013 notes, and accrued interest through October 7, 2014, into 1,637,846 shares of common stock immediately prior to the closing of this offering;a reverse stock split of 1-for-15 of our common stock and preferred stock effected on February 3, 2014

from December 31, 2013 to March 31, 2014 Conversion of preferred stock to common stock in connection with initial public offering Issuance of common stock in connection with initial public offering, net of underwriting discounts, commissions and issuance costs of $11.8 million Issuance of common stock upon conversion of 2013 convertible notes in connection with initial public offering Issuance of common stock upon net exercise of common stock warrants and related extinguishment of warrant liability in connection with initial public offering Issuance of common stock upon exercise of stock options Issuance of common stock at $15.45 per share for services rendered adjusted for the 1-for-15 reverse stock split effected on February 3, 2014

the conversion of all outstanding shares of our convertible preferred stock into an aggregate of 8,689,999 shares of our common stock, which will occur upon the closing of this offering;the automatic conversion of the $23.65 million in aggregate principal amount of convertible promissory notes issued in the fourth quarter of 2013 and January 2014, or the 2013 notes, and accrued interest through October 7, 2014, into 1,637,846 shares of common stock immediately prior to the closing of this offering;a reverse stock split of 1-for-15 of our common stock and preferred stock effected on February 3, 2014

In January 2014, the Company’s Board of Directors and stockholders approved an amended and restated certificate of incorporation effecting a 1-for-15 reverse stock split of the Company’s issued and outstanding shares of common stock and convertible preferred stock. The reverse split was effected on February 3, 2014.

from December 31,2012 to December 31,2013 Conversion of Series D convertible preferred stock into Series E-3 convertible preferred stock Conversion of 2011 Notes into Series E-4 convertible preferred stock Issuance of Series E-5 convertible preferred stock for cash at $22.50 per share in February through May 2013, net of issuance costs of $132 Issuance of Series E-5 convertible preferred stock as a deemed dividend Expiration of note payable from stockholder, Series E-1 Exercise of stock options at $2.55 per share Exercise of common stock warrants at $0.15 per share

From December 31, 2012 to September 30, 2013 Conversion of Series D convertible preferred stock into Series E-3 convertible preferred stock Conversion of Convertible Notes into Series E-4 convertible preferred stock Issuance of Series E-5 convertible preferred stock for cash at $1.50 per share in February through May 2013, net of issuance costs of $64 Issuance of Series E-5 convertible preferred stock as a deemed dividend Expiration of note payable from stockholder, Series E-1 Exercise of stock options at $0.17 per share Exercise of common stock warrants at $0.01 per share